ArticleBiochemical and biophysical research communications2008
Rational design of minimal hypoxia-inducible enhancers.
Article in Biochemical and biophysical research communications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- An engineered hypoxia-response promoter for human umbilical cord-derived mesenchymal stem cell-based therapeutics.BMC biotechnology · 2025Article
- Article
- Molecular Mechanisms Involved in Hypoxia-Induced Alterations in Bone Remodeling.International journal of molecular sciences · 2022Review
- Molecular and Supramolecular Structure of the Mitochondrial Oxidative Phosphorylation System: Implications for Pathology.Life (Basel, Switzerland) · 2021Review
- Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Development of a real-time imaging system for hypoxic cell apoptosis.Molecular therapy. Methods & clinical development · 2016Article
- Suppressors of superoxide production from mitochondrial complex III.Nature chemical biology · 2015Article
- Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation.Oncology letters · 2015Article
- Selective enhancement of hypoxic cell killing by tempol-regulated suicide gene expression.Oncology reports · 2015Article
- PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases.Clinical science (London, England : 1979) · 2015Review
- Combinatorial control of transgene expression by hypoxia-responsive promoter and microrna regulation for neural stem cell-based cancer therapy.BioMed research international · 2014Article
- Relevance of mitochondrial genetics and metabolism in cancer development.Cold Spring Harbor perspectives in biology · 2013Review
- Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease.Experimental and therapeutic medicine · 2012Article
- Improvement and induction property of radiation-responsive promoter through DNA shuffling of 5'-flanking regions of the human p21 gene.Journal of bioscience and bioengineering · 2010Article
- Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?Biochimica et biophysica acta · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The hypoxia-inducible factor (HIF) activates transcription via binding to the highly variable hypoxia-responsive elements (HREs). All hypoxia-inducible constructs described to date utilize multimers of naturally occurring HREs. Here, we describe the rational design of minimal hypoxia-inducible enhancers, conceptually equivalent to using an optimized HIF-binding site (HBS) as the building block. Optimizations of the HBS, spacing between HBSs, the distance from the minimal promoter, and orientation of HBSs allowed us to design constructs with high hypoxic activity. Activation of the 4xopt HBS (36bp) construct by hypoxia or HIF-1alpha and HIF-2alpha was comparable with that of the 4xEPO HRE (208bp) construct. The strong synergism between the properly arranged optimized HBSs was due to stimulation of high affinity HIF binding. Our data prove, for the first time, that it is possible to assemble artificial hypoxia-inducible enhancers from a single type of regulatory element-optimized HBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.